PIK3CA and breast carcinoma: Alpelisib demonstrates tolerable safety and favorable clinical efficiency in patients with PIK3CA-altered, HR-positive, HER2-negative breast cancer in combination with fulvestrant [255, 258–260] or letrozole [261] (Fig. 3l).